Item Type | Name |
Academic Article
|
Persistence of self-renewing leukemia cell progenitors during remission in children with B-precursor acute lymphoblastic leukemia.
|
Academic Article
|
Physiology and pathophysiology of dendritic cells.
|
Academic Article
|
Heterogeneity in lineage derivation of Philadelphia-positive acute lymphoblastic leukemia expressing p190BCR-ABL or p210BCR-ABL: determination by analysis of individual colonies with the polymerase chain reaction.
|
Academic Article
|
Expression of Bcl-2-related genes in normal and AML progenitors: changes induced by chemotherapy and retinoic acid.
|
Academic Article
|
High levels of vascular endothelial growth factor receptor-2 correlate with shortened survival in chronic lymphocytic leukemia.
|
Academic Article
|
Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax).
|
Academic Article
|
The synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces caspase-dependent and -independent apoptosis in acute myelogenous leukemia.
|
Academic Article
|
Deletion of TAK1 in the myeloid lineage results in the spontaneous development of myelomonocytic leukemia in mice.
|
Academic Article
|
Kit inhibitor APcK110 induces apoptosis and inhibits proliferation of acute myeloid leukemia cells.
|
Academic Article
|
Kit inhibitor APcK110 extends survival in an AML xenograft mouse model.
|
Academic Article
|
Measurement of residual leukemia during remission in childhood acute lymphoblastic leukemia.
|
Concept
|
Leukemia, Hairy Cell
|
Concept
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma
|
Concept
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
Concept
|
Leukemia, Erythroblastic, Acute
|
Concept
|
Leukemia, Radiation-Induced
|
Concept
|
Leukemia Inhibitory Factor Receptor alpha Subunit
|
Concept
|
Leukemia, B-Cell
|
Concept
|
Leukemia, Myelomonocytic, Chronic
|
Concept
|
Leukemia, Myeloid, Accelerated Phase
|
Concept
|
Leukemia, Monocytic, Acute
|
Concept
|
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
|
Concept
|
Myeloid-Lymphoid Leukemia Protein
|
Concept
|
Leukemia, Promyelocytic, Acute
|
Concept
|
Leukemia, Experimental
|
Concept
|
Leukemia, Lymphoid
|
Concept
|
Leukemia, Myelomonocytic, Acute
|
Concept
|
Leukemia Inhibitory Factor
|
Concept
|
Leukemia, Myeloid
|
Concept
|
Leukemia
|
Concept
|
Leukemia, Myeloid, Acute
|
Concept
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
|
Concept
|
Leukemia, Prolymphocytic, T-Cell
|
Concept
|
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
|
Concept
|
Leukemia, Biphenotypic, Acute
|
Concept
|
Leukemia, Lymphocytic, Chronic, B-Cell
|
Concept
|
Leukemia, Myeloid, Chronic-Phase
|
Concept
|
Leukemia, Large Granular Lymphocytic
|
Academic Article
|
Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance.
|
Academic Article
|
AMN107, a novel aminopyrimidine inhibitor of p190 Bcr-Abl activation and of in vitro proliferation of Philadelphia-positive acute lymphoblastic leukemia cells.
|
Academic Article
|
Atypical chronic lymphocytic leukemia with polyglandular autoimmune endocrinopathy type II: a complex profile.
|
Academic Article
|
Final report of phase II study of sorafenib, cytarabine and idarubicin for initial therapy in younger patients with acute myeloid leukemia.
|
Academic Article
|
Central role of tumour necrosis factor, GM-CSF, and interleukin 1 in the pathogenesis of juvenile chronic myelogenous leukaemia.
|
Academic Article
|
Synergistic antiproliferative effect of interferon alpha and azidothymidine in chronic myelogenous leukemia.
|
Academic Article
|
Juvenile chronic myelogenous leukemia.
|
Academic Article
|
Detection of residual acute lymphoblastic leukemia cells in cultures of bone marrow obtained during remission.
|
Academic Article
|
In vitro and in vivo effects of deferoxamine in neonatal acute leukemia.
|
Academic Article
|
B-lineage lymphoid blast crisis in juvenile chronic myelogenous leukemia: II. Interleukin-1-mediated autocrine growth regulation of the lymphoblasts.
|
Academic Article
|
The effect of growth hormone and IGF-I on clonogenic growth of hematopoietic cells in leukemic patients during active disease and during remission--a preliminary report.
|
Academic Article
|
Leukemia inhibitory factor binds to human breast cancer cells and stimulates their proliferation.
|
Academic Article
|
Leukemia-inhibitory factor stimulates breast, kidney and prostate cancer cell proliferation by paracrine and autocrine pathways.
|
Academic Article
|
Z-138: a new mature B-cell acute lymphoblastic leukemia cell line from a patient with transformed chronic lymphocytic leukemia.
|
Academic Article
|
Residual disease in acute lymphoblastic leukemia of childhood: methods of detection and clinical relevance.
|
Academic Article
|
Caspase 2 and caspase 3 protein levels as predictors of survival in acute myelogenous leukemia.
|
Academic Article
|
Detection of residual disease in acute lymphoblastic leukemia of childhood.
|
Academic Article
|
Autocrine interleukin-1beta production in leukemia: evidence for the involvement of mutated RAS.
|
Academic Article
|
The biology of chronic myeloid leukemia.
|
Academic Article
|
The prognostic significance of p16INK4a/p14ARF and p15INK4b deletions in adult acute lymphoblastic leukemia.
|
Academic Article
|
Monitoring of residual disease in chronic myelogenous leukemia by quantitative polymerase chain reaction and clinical decision making.
|
Academic Article
|
Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia.
|
Academic Article
|
Liposomal Bcl-2 antisense oligonucleotides enhance proliferation, sensitize acute myeloid leukemia to cytosine-arabinoside, and induce apoptosis independent of other antiapoptotic proteins.
|
Academic Article
|
Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes.
|
Academic Article
|
N-(4-Hydroxylphenyl)retinamide (fenretinide, 4-HPR), a retinoid compound with antileukemic and proapoptotic activity in acute lymphoblastic leukemia (ALL).
|
Academic Article
|
Commentary: effect of flavonoids on normal and leukemic cells.
|
Academic Article
|
A novel ring-substituted diindolylmethane,1,1-bis[3'-(5-methoxyindolyl)]-1-(p-t-butylphenyl) methane, inhibits extracellular signal-regulated kinase activation and induces apoptosis in acute myelogenous leukemia.
|
Academic Article
|
WP1066 disrupts Janus kinase-2 and induces caspase-dependent apoptosis in acute myelogenous leukemia cells.
|
Academic Article
|
Enzymatic activity of circulating proteasomes correlates with clinical behavior in patients with chronic lymphocytic leukemia.
|
Academic Article
|
WP1066, a novel JAK2 inhibitor, suppresses proliferation and induces apoptosis in erythroid human cells carrying the JAK2 V617F mutation.
|
Academic Article
|
Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia.
|
Academic Article
|
Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin.
|
Academic Article
|
Circulating Ki-67 protein in plasma as a biomarker and prognostic indicator of acute lymphoblastic leukemia.
|
Academic Article
|
Cytogenetic abnormalities in essential thrombocythemia at presentation and transformation.
|
Academic Article
|
Clinical correlation of circulating heat shock protein 70 in acute leukemia.
|
Academic Article
|
Survival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapy.
|
Academic Article
|
The synthetic heat shock protein 90 (Hsp90) inhibitor EC141 induces degradation of Bcr-Abl p190 protein and apoptosis of Ph-positive acute lymphoblastic leukemia cells.
|
Academic Article
|
Recurrent expression signatures of cytokines and chemokines are present and are independently prognostic in acute myelogenous leukemia and myelodysplasia.
|
Academic Article
|
Treatment with lenalidomide modulates T-cell immunophenotype and cytokine production in patients with chronic lymphocytic leukemia.
|
Academic Article
|
Acute lymphoblastic leukemia arising in post-polycythemic myelofibrosis: a rare entity.
|
Academic Article
|
A phase II study of lenalidomide alone in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes with chromosome 5 abnormalities.
|
Academic Article
|
A randomized study of decitabine versus conventional care for maintenance therapy in patients with acute myeloid leukemia in complete remission.
|
Academic Article
|
Dynamic acquisition of FLT3 or RAS alterations drive a subset of patients with lower risk MDS to secondary AML.
|
Academic Article
|
Small molecule ErbB inhibitors decrease proliferative signaling and promote apoptosis in philadelphia chromosome-positive acute lymphoblastic leukemia.
|
Academic Article
|
Inhibition of acute myelogenous leukemia blast proliferation by interleukin-1 (IL-1) receptor antagonist and soluble IL-1 receptors.
|
Academic Article
|
Comparison of in vivo and in vitro effects of granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with acute myeloid leukemia.
|
Academic Article
|
Erythropoietin treatment in patients with myelodysplastic syndrome and anemia.
|
Academic Article
|
Acute lymphoblastic leukemia blast cells do not inhibit bone marrow hematopoietic progenitor colony formation.
|
Academic Article
|
Recombinant human interferon alpha-2 and juvenile chronic myelogenous leukemia: cell receptor binding, enzymatic induction, and growth suppression in vitro.
|
Academic Article
|
Synergistic antiproliferative effects on HL-60 cells: deferoxamine enhances cytosine arabinoside, methotrexate, and daunorubicin cytotoxicity.
|
Academic Article
|
Clinical utility of marrow cell tissue cultures in acute leukemia of childhood.
|
Academic Article
|
Juvenile chronic myelogenous leukemia: characterization of the disease using cell cultures.
|
Academic Article
|
Clinical and in vitro antiproliferative properties of recombinant DNA-derived human interferon-alpha 2.
|
Academic Article
|
Candidemia and sternal Candida albicans osteomyelitis in a patient with chronic lymphatic leukemia.
|
Academic Article
|
Granulocyte-colony stimulating factor, granulocyte-macrophage colony stimulating factor, PIXY-321, stem cell factor, interleukin-3, and interleukin-7: receptor binding and effects on clonogenic proliferation in acute lymphoblastic leukemia.
|
Academic Article
|
Cytokines and their antagonists in myeloid disorders.
|
Academic Article
|
Altered levels of interleukin-1 beta and interleukin-1 receptor antagonist in chronic myelogenous leukemia: clinical and prognostic correlates.
|
Academic Article
|
Inhibition of acute myelogenous leukemia progenitor proliferation by macrophage inflammatory protein 1-alpha.
|
Academic Article
|
CML: mechanisms of disease initiation and progression.
|
Academic Article
|
The clinical significance of residual disease in childhood acute lymphoblastic leukemia as detected by polymerase chain reaction amplification by antigen-receptor gene sequences.
|
Academic Article
|
Molecular and biologic characterization of a newly established Philadelphia-positive acute lymphoblastic leukemia cell line (Z-33) with an autocrine response to GM-CSF.
|
Academic Article
|
Identification of human juvenile chronic myelogenous leukemia stem cells capable of initiating the disease in primary and secondary SCID mice.
|
Academic Article
|
Monitoring residual disease in acute lymphoblastic leukemia: therapeutic implications.
|
Academic Article
|
Interleukin-1 and its inhibitors: a biologic and therapeutic model for the role of growth regulatory factors in leukemias.
|
Academic Article
|
Conversion of interferon-induced, long-term cytogenetic remissions in chronic myelogenous leukemia to polymerase chain reaction negativity.
|
Academic Article
|
Clinical significance of cytogenetic abnormalities in adult acute lymphoblastic leukemia.
|
Academic Article
|
Should polymerase chain reaction analysis to detect minimal residual disease in patients with chronic myelogenous leukemia be used in clinical decision making?
|
Academic Article
|
Minimal residual disease in hematologic disorders.
|
Academic Article
|
Polymerase chain reaction analyses should be used as a basis for clinical decision making in patients with chronic myelogenous leukemia.
|
Academic Article
|
Outcome of Philadelphia chromosome-positive adult acute lymphoblastic leukemia.
|
Academic Article
|
Clinical significance of minimal residual disease in leukemia.
|
Academic Article
|
Expression of apoptosis proteins in chronic myelogenous leukemia: associations and significance.
|
Academic Article
|
Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia.
|
Academic Article
|
Shift of immunoglobulin phenotypes in B-cell precursor cell lines.
|
Academic Article
|
Inhibition of phosphatidylinositol 3-kinase dephosphorylates BAD and promotes apoptosis in myeloid leukemias.
|
Academic Article
|
Pharmacodynamics of cytarabine alone and in combination with 7-hydroxystaurosporine (UCN-01) in AML blasts in vitro and during a clinical trial.
|
Academic Article
|
OSW-1: a natural compound with potent anticancer activity and a novel mechanism of action.
|
Academic Article
|
Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older.
|
Academic Article
|
Eradication of leukemia stem cells as a new goal of therapy in leukemia.
|
Academic Article
|
Atiprimod blocks phosphorylation of JAK-STAT and inhibits proliferation of acute myeloid leukemia (AML) cells.
|
Academic Article
|
Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia.
|
Academic Article
|
Distinct biological impact of dephosphorylation vs. downregulation of p210Bcr-Abl: implications for imatinib mesylate response and resistance.
|
Academic Article
|
Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia.
|
Academic Article
|
Blockade of adaptive defensive changes in cholesterol uptake and synthesis in AML by the addition of pravastatin to idarubicin + high-dose Ara-C: a phase 1 study.
|
Academic Article
|
Soluble syndecan-1 (sCD138) as a prognostic factor independent of mutation status in patients with chronic lymphocytic leukemia.
|
Academic Article
|
Circulating heat shock protein 70 and progression in patients with chronic myeloid leukemia.
|
Academic Article
|
Incidence of extramedullary disease in patients with acute promyelocytic leukemia: a single-institution experience.
|
Academic Article
|
STAT3 is constitutively phosphorylated on serine 727 residues, binds DNA, and activates transcription in CLL cells.
|
Academic Article
|
Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia.
|
Academic Article
|
Homologous recombination as a resistance mechanism to replication-induced double-strand breaks caused by the antileukemia agent CNDAC.
|
Academic Article
|
Genome-wide DNA methylation profiling of chronic lymphocytic leukemia allows identification of epigenetically repressed molecular pathways with clinical impact.
|
Academic Article
|
A phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome.
|
Academic Article
|
STAT-3 activates NF-kappaB in chronic lymphocytic leukemia cells.
|
Academic Article
|
Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia.
|
Academic Article
|
Ocular granulocytic sarcoma: a case report and literature review of ocular extramedullary acute myeloid leukemia.
|
Academic Article
|
Prognostic significance of 11q23 aberrations in adult acute myeloid leukemia and the role of allogeneic stem cell transplantation.
|
Academic Article
|
Is acute myeloid leukemia a liquid tumor?
|
Academic Article
|
Central nervous system Richter's transformation and parvovirus B19 infection.
|
Academic Article
|
Salvage therapy using FLT3 inhibitors may improve long-term outcome of relapsed or refractory AML in patients with FLT3-ITD.
|
Academic Article
|
Signal transducer and activator of transcription-3 induces microRNA-155 expression in chronic lymphocytic leukemia.
|
Academic Article
|
Acquisition of cytogenetic abnormalities in patients with IPSS defined lower-risk myelodysplastic syndrome is associated with poor prognosis and transformation to acute myelogenous leukemia.
|
Academic Article
|
Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients =60 years with newly diagnosed acute myeloid leukemia.
|
Academic Article
|
Statin and aspirin use is associated with improved outcome of FCR therapy in relapsed/refractory chronic lymphocytic leukemia.
|
Academic Article
|
Correlation between FDG/PET, histology, characteristics, and survival in 332 patients with chronic lymphoid leukemia.
|
Academic Article
|
Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL.
|
Academic Article
|
The modulatory hematopoietic activities of leukemia inhibitory factor.
|
Academic Article
|
The effect of granulocyte-macrophage colony-stimulating factor on undifferentiated and mature acute myelogenous leukemia blast progenitors.
|
Academic Article
|
Differentiation in B-precursor acute lymphoblastic leukemia cell populations with CD34-positive subpopulations.
|
Academic Article
|
Suppression of chronic myelogenous leukemia colony growth by interleukin-1 (IL-1) receptor antagonist and soluble IL-1 receptors: a novel application for inhibitors of IL-1 activity.
|
Academic Article
|
Human growth hormone and insulin-like growth factor-1 enhance the proliferation of human leukemic blasts.
|
Academic Article
|
The value of intensive combination chemotherapy for juvenile chronic myelogenous leukemia.
|
Academic Article
|
Circulating mononuclear cells from pure red cell aplasia of chronic lymphocytic leukemia suppress in vitro erythropoiesis.
|
Academic Article
|
[Recent advances in juvenile chronic myelogenous leukemia].
|
Academic Article
|
Effect of deferoxamine on DNA synthesis, DNA repair, cell proliferation, and differentiation of HL-60 cells.
|
Academic Article
|
Characterization of malignant peripheral blood cells of juvenile chronic myelogenous leukemia.
|
Academic Article
|
Residual juvenile chronic myelogenous leukemia cells detected in peripheral blood during clinical remission.
|
Academic Article
|
Growth inhibitory effect of gene-cloned interferons on human myeloblast colonies.
|
Academic Article
|
High incidence of acute myeloid leukemia in SJL/J mice after X-irradiation and corticosteroids.
|
Academic Article
|
Dosing of thioTEPA for myeloablative therapy.
|
Academic Article
|
Role of suramin as an IL-1 inhibitor in suppression of acute myelogenous leukemia progenitor proliferation.
|
Academic Article
|
Interruption of autocrine and paracrine growth-stimulatory mechanisms: a new therapeutic strategy for chronic myelogenous leukemia.
|
Academic Article
|
Chronic myelogenous leukemia: a concise update.
|
Academic Article
|
Lymphotoxin is an autocrine growth factor for Epstein-Barr virus-infected B cell lines.
|
Academic Article
|
Effect of interleukin-1 beta converting enzyme inhibitor on acute myelogenous leukemia progenitor proliferation.
|
Academic Article
|
Role of interleukin-1 beta converting enzyme (ICE) in acute myelogenous leukemia cell proliferation and programmed cell death.
|
Academic Article
|
Expression of leukemia inhibitory factor and its receptor in breast cancer: a potential autocrine and paracrine growth regulatory mechanism.
|
Academic Article
|
Oncostatin M-specific receptor expression and function in regulating cell proliferation of normal and malignant mammary epithelial cells.
|
Academic Article
|
Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148).
|
Academic Article
|
Thrombopoietin stimulates myelodysplastic syndrome granulocyte-macrophage and erythroid progenitor proliferation.
|
Academic Article
|
Ligation of cell surface CD38 protein with agonistic monoclonal antibody induces a cell growth signal in myeloid leukemia cells.
|
Academic Article
|
Correlation between lower c-mpl protein expression and favorable cytogenetic groups in acute myeloid leukemia.
|
Academic Article
|
Expression and function of leptin receptor isoforms in myeloid leukemia and myelodysplastic syndromes: proliferative and anti-apoptotic activities.
|
Academic Article
|
Chronic myelogenous leukemia: biology and therapy.
|
Academic Article
|
Phenylarsine oxide blocks interleukin-1beta-induced activation of the nuclear transcription factor NF-kappaB, inhibits proliferation, and induces apoptosis of acute myelogenous leukemia cells.
|
Academic Article
|
Caspase 2 and caspase 3 as predictors of complete remission and survival in adults with acute lymphoblastic leukemia.
|
Academic Article
|
The incidence of chromosome 9p21 abnormalities and deletions of tumor suppressor genes p15(INK4b)/p16(INK4a)/p14(ARF) in patients with acute lymphoblastic leukemia.
|
Academic Article
|
Cell-penetrating SH3 domain blocker peptides inhibit proliferation of primary blast cells from CML patients.
|
Academic Article
|
The prognostic significance of p16(INK4a)/p14(ARF) locus deletion and MDM-2 protein expression in adult acute myelogenous leukemia.
|
Academic Article
|
Studies of minimal residual disease in acute lymphocytic leukemia.
|
Academic Article
|
Expression of a truncated first exon BCR sequence in chronic myelogenous leukemia cells blocks cell growth and induces cell death.
|
Academic Article
|
Comparison of outcome in acute myelogenous leukemia patients with translocation (8;21) found by standard cytogenetic analysis and patients with AML1/ETO fusion transcript found only by PCR testing.
|
Academic Article
|
The clinical significance of caspase regulation in acute leukemia.
|
Academic Article
|
Novel triterpenoid CDDO-Me is a potent inducer of apoptosis and differentiation in acute myelogenous leukemia.
|
Academic Article
|
WP744, a novel anthracycline with enhanced proapoptotic and antileukemic activity.
|
Academic Article
|
Synergistic induction of apoptosis by simultaneous disruption of the Bcl-2 and MEK/MAPK pathways in acute myelogenous leukemia.
|
Academic Article
|
CD56 expression predicts occurrence of CNS disease in acute lymphoblastic leukemia.
|
Academic Article
|
The clinical significance of tumor necrosis factor-alpha plasma level in patients having chronic lymphocytic leukemia.
|
Academic Article
|
Granulocyte-macrophage colony-stimulating factor (GM-CSF) induces antiapoptotic and proapoptotic signals in acute myeloid leukemia.
|
Academic Article
|
Autocrine lymphotoxin production in Epstein-Barr virus-immortalized B cells: induction via NF-kappaB activation mediated by EBV-derived latent membrane protein 1.
|
Academic Article
|
Hematopoietic recovery following induction therapy of acute leukemias: prognostic implications and a new look at the definition of remission.
|
Academic Article
|
Aberrant morphology, proliferation, and apoptosis of B-cell chronic lymphocytic leukemia cells.
|
Academic Article
|
WP-1034, a novel JAK-STAT inhibitor, with proapoptotic and antileukemic activity in acute myeloid leukemia (AML).
|
Academic Article
|
Adaphostin-induced oxidative stress overcomes BCR/ABL mutation-dependent and -independent imatinib resistance.
|
Academic Article
|
Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia.
|
Academic Article
|
Studying the right cell in acute myelogenous leukemia: dynamic changes of apoptosis and signal transduction pathway protein expression in chemotherapy resistant ex-vivo selected "survivor cells".
|
Academic Article
|
Activation of a novel Bcr/Abl destruction pathway by WP1130 induces apoptosis of chronic myelogenous leukemia cells.
|
Academic Article
|
Biphenotypic acute leukaemia: a case series.
|
Academic Article
|
Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome.
|
Academic Article
|
Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia.
|
Academic Article
|
A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome.
|
Academic Article
|
Proteasome enzymatic activities in plasma as risk stratification of patients with acute myeloid leukemia and advanced-stage myelodysplastic syndrome.
|
Academic Article
|
Inhibition of KSP by ARRY-520 induces cell cycle block and cell death via the mitochondrial pathway in AML cells.
|
Academic Article
|
The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up.
|
Academic Article
|
Circulating Ki-67 index in plasma as a biomarker and prognostic indicator in chronic lymphocytic leukemia.
|
Academic Article
|
Stat3 activates the receptor tyrosine kinase like orphan receptor-1 gene in chronic lymphocytic leukemia cells.
|
Academic Article
|
Persistence of cytogenetic abnormalities at complete remission after induction in patients with acute myeloid leukemia: prognostic significance and the potential role of allogeneic stem-cell transplantation.
|
Academic Article
|
Phase I-II study of bendamustine in patients with acute leukemia and high risk myelodysplastic syndrome.
|
Academic Article
|
Epstein-Barr virus-induced CD30-positive diffuse large B-cell lymphoma in a patient with mixed-phenotypic leukemia treated with clofarabine.
|
Academic Article
|
Azacitidine in fludarabine-refractory chronic lymphocytic leukemia: a phase II study.
|
Academic Article
|
The significance of spliceosome mutations in chronic lymphocytic leukemia.
|
Academic Article
|
Spontaneous remission of chemo-immunotherapy related, non-transplant Epstein-Barr virus-associated lymphoproliferative disorder in a patient with chronic lymphocytic leukemia.
|
Academic Article
|
CD4(-)/CD8(-) variant of T-cell large granular lymphocytic leukemia or hepatosplenic T-cell lymphoma: a clinicopathologic dilemma.
|
Academic Article
|
Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia.
|
Academic Article
|
Personalized medicine in CLL: current status and future perspectives.
|
Academic Article
|
Detection of dormant chronic myeloid leukemia clones in the bone marrow of patients in complete molecular remission.
|
Academic Article
|
Stimulation of the B-cell receptor activates the JAK2/STAT3 signaling pathway in chronic lymphocytic leukemia cells.
|
Academic Article
|
Growth requirements for human acute lymphoblastic leukemia cells: refinement of a clonogenic assay.
|
Academic Article
|
Chronic myeloid leukemia following radiotherapy for breast cancer.
|
Academic Article
|
Detection of minimal residual disease in acute lymphoblastic leukemia.
|
Academic Article
|
Accurate quantitation of residual B-precursor acute lymphoblastic leukemia by limiting dilution and a PCR-based detection system: a description of the method and the principles involved.
|
Academic Article
|
Persistence of dormant leukemic progenitors during interferon-induced remission in chronic myelogenous leukemia. Analysis by polymerase chain reaction of individual colonies.
|
Academic Article
|
Leukemia inhibitory factor in long-term adherent layer cultures: increased levels of bioactive protein in leukemia and modulation by IL-4, IL-1 beta, and TNF-alpha.
|
Academic Article
|
Ubiquitous expression of cytokines in diverse leukemias of lymphoid and myeloid lineage.
|
Academic Article
|
Suppression of chronic myelogenous leukemia colony growth by interleukin-4.
|
Academic Article
|
Human recombinant interferon-inducible protein-10 inhibits the proliferation of normal and acute myelogenous leukemia progenitors.
|
Academic Article
|
Flt3 ligand stimulates proliferation and inhibits apoptosis of acute myeloid leukemia cells: regulation of Bcl-2 and Bax.
|
Academic Article
|
1,25-Dihydroxyvitamin D3 and its analogues inhibit acute myelogenous leukemia progenitor proliferation by suppressing interleukin-1beta production.
|
Academic Article
|
DNA in situ hybridization of individual colonies to determine lineage derivation in leukemia.
|
Academic Article
|
Detection of residual disease in childhood acute lymphoblastic leukemia.
|
Academic Article
|
Apoptosis. Molecules and mechanisms.
|
Academic Article
|
Inhibition of acute lymphoblastic and myeloid leukemias by a novel kinase inhibitor.
|
Academic Article
|
Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias.
|
Academic Article
|
The anti-angiogenesis agent, AG-013736, has minimal activity in elderly patients with poor prognosis acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
|
Academic Article
|
Plasma thrombopoietin compared with immunoglobulin heavy-chain mutation status as a predictor of survival in chronic lymphocytic leukemia.
|
Academic Article
|
Triptolide induces caspase-dependent cell death mediated via the mitochondrial pathway in leukemic cells.
|
Academic Article
|
Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy.
|
Academic Article
|
Clofarabine combinations as acute myeloid leukemia salvage therapy.
|
Academic Article
|
The leukemia stem cell.
|
Academic Article
|
Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia.
|
Academic Article
|
Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy.
|
Academic Article
|
LIF: not just a leukemia inhibitory factor.
|
Academic Article
|
Cytokine expression in adherent layers from patients with myelodysplastic syndrome and acute myelogenous leukemia.
|
Academic Article
|
Immature and differentiated neoplastic populations in acute lymphoid leukemia of childhood: biological and clinical implications.
|
Academic Article
|
Role of interleukin-1 inhibitory molecules in therapy of acute and chronic myelogenous leukemia.
|
Academic Article
|
Role of granulocyte-macrophage colony-stimulating factor in Philadelphia (Ph1)-positive acute lymphoblastic leukemia: studies on two newly established Ph1-positive acute lymphoblastic leukemia cell lines (Z-119 and Z-181).
|
Academic Article
|
Suppressed formation of bone marrow adherent layers derived from acute myeloid leukemia patients after in vitro exposure to interleukin-4.
|
Academic Article
|
Role of interleukin-1 beta converting enzyme (ICE) in leukemia.
|
Academic Article
|
The prognostic impact of BCL2 protein expression in acute myelogenous leukemia varies with cytogenetics.
|
Academic Article
|
BAX and PKCalpha modulate the prognostic impact of BCL2 expression in acute myelogenous leukemia.
|
Academic Article
|
Proliferation and apoptosis in acute and chronic leukemias and myelodysplastic syndrome.
|
Academic Article
|
Resveratrol blocks interleukin-1beta-induced activation of the nuclear transcription factor NF-kappaB, inhibits proliferation, causes S-phase arrest, and induces apoptosis of acute myeloid leukemia cells.
|
Academic Article
|
Expression of constitutively active nuclear-kappa B RelA transcription factor in blasts of acute myeloid leukemia.
|
Academic Article
|
Simultaneous inhibition of PDK1/AKT and Fms-like tyrosine kinase 3 signaling by a small-molecule KP372-1 induces mitochondrial dysfunction and apoptosis in acute myelogenous leukemia.
|
Academic Article
|
Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.
|
Academic Article
|
Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia.
|
Academic Article
|
Ubiquitin-proteasome system profiling in acute leukemias and its clinical relevance.
|
Academic Article
|
Cross-talk between chronic lymphocytic leukemia cells and bone marrow endothelial cells: role of signal transducer and activator of transcription 3.
|
Academic Article
|
Chronic lymphocytic leukemia with central nervous system involvement: a high-risk disease?
|
Academic Article
|
Signal transducer and activator of transcription (STAT)-3 regulates microRNA gene expression in chronic lymphocytic leukemia cells.
|
Academic Article
|
Targeting inflammatory pathways in chronic lymphocytic leukemia.
|
Academic Article
|
Interaction between myelomonocytic and lymphoid cells in a patient with acute myelomonocytic leukemia and chronic lymphocytic leukemia.
|
Academic Article
|
The PI3-kinase delta inhibitor idelalisib (GS-1101) targets integrin-mediated adhesion of chronic lymphocytic leukemia (CLL) cell to endothelial and marrow stromal cells.
|
Academic Article
|
Interleukin-7 receptor-a gene mutations are not detected in adult T-cell acute lymphoblastic leukemia.
|
Academic Article
|
Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations.
|
Academic Article
|
STAT3-activated GM-CSFRa translocates to the nucleus and protects CLL cells from apoptosis.
|
Academic Article
|
A prognostic model of therapy-related myelodysplastic syndrome for predicting survival and transformation to acute myeloid leukemia.
|
Academic Article
|
FCR and bevacizumab treatment in patients with relapsed chronic lymphocytic leukemia.
|
Academic Article
|
Myeloid neoplasms after breast cancer: "therapy-related" not an independent poor prognostic factor.
|
Academic Article
|
Incidence of and risk factors for involvement of the central nervous system in acute myeloid leukemia.
|
Academic Article
|
Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes.
|
Academic Article
|
Phase II study of methotrexate, vincristine, pegylated-asparaginase, and dexamethasone (MOpAD) in patients with relapsed/refractory acute lymphoblastic leukemia.
|
Academic Article
|
Very high levels of lactate dehydrogenase at diagnosis predict central nervous system relapse in acute promyelocytic leukaemia.
|
Academic Article
|
Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome.
|
Academic Article
|
Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib.
|
Academic Article
|
High fluorescence in situ hybridization percentage of deletion 11q in patients with chronic lymphocytic leukemia is an independent predictor of adverse outcome.
|
Academic Article
|
Aberrant LPL Expression, Driven by STAT3, Mediates Free Fatty Acid Metabolism in CLL Cells.
|
Academic Article
|
Outcomes of Patients With Chronic Lymphocytic Leukemia and Richter's Transformation After Transplantation Failure.
|
Academic Article
|
Disseminated histoplasmosis as pseudo Richter's transformation in a patient with chronic lymphocytic leukemia.
|
Academic Article
|
Association of lymphoid malignancies and Philadelphia-chromosome negative myeloproliferative neoplasms: Clinical characteristics, therapy and outcome.
|
Academic Article
|
Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens.
|
Academic Article
|
Fludarabine, cyclophosphamide, and multiple-dose rituximab as frontline therapy for chronic lymphocytic leukemia.
|
Academic Article
|
Epstein-Barr Virus MicroRNAs are Expressed in Patients with Chronic Lymphocytic Leukemia and Correlate with Overall Survival.
|
Academic Article
|
Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
|
Academic Article
|
Acute myeloid leukemia with MYC rearrangement and JAK2 V617F mutation.
|
Academic Article
|
Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study.
|
Academic Article
|
Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia.
|
Academic Article
|
Fludarabine, cyclophosphamide, and multiple-dose rituximab as frontline therapy for chronic lymphocytic leukemia
|
Academic Article
|
Clinical and molecular characteristics of XPO1 mutations in patients with chronic lymphocytic leukemia
|
Academic Article
|
Epstein-Barr Virus MicroRNAs are Expressed in Patients with Chronic Lymphocytic Leukemia and Correlate with Overall Survival
|
Academic Article
|
Clofarabine Plus Low-Dose Cytarabine Is as Effective as and Less Toxic Than Intensive Chemotherapy in Elderly AML Patients
|
Academic Article
|
DNMT3A, TET2, and JAK2 mutations in polycythemia vera following long-term remission of secondary acute myeloid leukemia
|
Academic Article
|
Relapsed refractory BRAF-negative, IGHV4-34-positive variant of hairy cell leukemia
|
Academic Article
|
Autoimmune cytopenias in patients with chronic lymphocytic leukemia treated with ibrutinib
|
Academic Article
|
Elimination of chronic lymphocytic leukemia cells in stromal microenvironment by targeting CPT with an antiangina drug perhexiline
|
Academic Article
|
At high levels, constitutively activated STAT3 induces apoptosis of chronic lymphocytic leukemia cells
|
Academic Article
|
Secondary solid tumors and lymphoma in patients with essential thrombocythemia and polycythemia vera - Single center experience
|
Academic Article
|
A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials
|
Academic Article
|
Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia
|
Academic Article
|
Metabolism pathways in chronic lymphocytic leukemia
|
Academic Article
|
Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy
|
Academic Article
|
Incidence of and risk factors for involvement of the central nervous system in acute myeloid leukemia
|
Academic Article
|
Acute myeloid leukemia with MYC rearrangement and JAK2 V617F mutation
|
Academic Article
|
FCR and bevacizumab treatment in patients with relapsed chronic lymphocytic leukemia
|
Academic Article
|
Myeloid neoplasms after breast cancer
|
Academic Article
|
β2-microglobulin normalization within 6 months of ibrutinib-based treatment is associated with superior progression-free survival in patients with chronic lymphocytic leukemia
|
Academic Article
|
Synchronous del5q myelodysplastic syndrome (del5qMDS) and adult B-cell acute lymphoblastic leukemia (B-ALL) with TET2 and TP53 mutations
|
Academic Article
|
Potential therapeutic utility of ICE inhibitors in leukemia
|
Academic Article
|
Chronic lymphocytic leukemia and myeloproliferative neoplasms concurrently diagnosed
|
Academic Article
|
Inihibition of PI3K by LY294002 promotes apoptosis and dephosphorylates bad in myeloid leukemias
|
Academic Article
|
Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens
|
Academic Article
|
TP53 mutations in newly diagnosed acute myeloid leukemia
|
Academic Article
|
Residual disease in acute lymphoblastic leukemia of childhood
|
Academic Article
|
Philadelphia-positive dimorphic blasts in mixed-phenotype acute leukemia with TET2 mutation
|
Academic Article
|
Functional differences between IgM and IgD signaling in chronic lymphocytic leukemia
|
Academic Article
|
A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials.
|
Academic Article
|
A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials.
|
Academic Article
|
Relapsed Refractory BRAF-Negative, IGHV4-34-Positive Variant of Hairy Cell Leukemia: A Distinct Entity?
|
Academic Article
|
Meir Wetzler, MD.
|
Academic Article
|
Chronic lymphocytic leukemia and myeloproliferative neoplasms concurrently diagnosed: clinical and biological characteristics.
|
Academic Article
|
Synchronous del5q myelodysplastic syndrome (del5qMDS) and adult B-cell acute lymphoblastic leukemia (B-ALL) with TET2 and TP53 mutations.
|
Academic Article
|
DNMT3A, TET2, and JAK2 mutations in polycythemia vera following long-term remission of secondary acute myeloid leukemia.
|
Academic Article
|
Clofarabine Plus Low-Dose Cytarabine Is as Effective as and Less Toxic Than Intensive Chemotherapy in Elderly AML Patients.
|
Academic Article
|
Autoimmune cytopenias in patients with chronic lymphocytic leukemia treated with ibrutinib.
|
Academic Article
|
At High Levels, Constitutively Activated STAT3 Induces Apoptosis of Chronic Lymphocytic Leukemia Cells.
|
Academic Article
|
?2 -microglobulin normalization within 6 months of ibrutinib-based treatment is associated with superior progression-free survival in patients with chronic lymphocytic leukemia.
|
Academic Article
|
Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors.
|
Academic Article
|
Philadelphia-positive dimorphic blasts in mixed-phenotype acute leukemia with TET2 mutation.
|
Academic Article
|
Metabolism pathways in chronic lymphocytic leukemia.
|
Academic Article
|
TP53 mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomes.
|
Academic Article
|
Elimination of chronic lymphocytic leukemia cells in stromal microenvironment by targeting CPT with an antiangina drug perhexiline.
|
Academic Article
|
Describing a Transcription Factor Dependent Regulation of the MicroRNA Transcriptome.
|
Academic Article
|
Clinical and molecular characteristics of XPO1 mutations in patients with chronic lymphocytic leukemia.
|
Academic Article
|
Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia.
|
Academic Article
|
Ocular extramedullary myeloid leukaemia.
|
Academic Article
|
Ibrutinib Therapy Increases T Cell Repertoire Diversity in Patients with Chronic Lymphocytic Leukemia.
|
Academic Article
|
Long-term Follow-up of Treatment with Ibrutinib and Rituximab in Patients with High-Risk Chronic Lymphocytic Leukemia.
|
Academic Article
|
Constitutive Phosphorylation of STAT3 by the CK2-BLNK-CD5 Complex.
|
Academic Article
|
Functional Differences between IgM and IgD Signaling in Chronic Lymphocytic Leukemia.
|
Academic Article
|
PET-positive lymphadenopathy in CLL-Not always Richter transformation.
|
Academic Article
|
Chronic myeloid leukemia among patients with a history of prior malignancies: A tale of dual survivorship.
|
Academic Article
|
Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab.
|
Academic Article
|
Ruxolitinib for symptom control in patients with chronic lymphocytic leukaemia: a single-group, phase 2 trial.
|
Academic Article
|
Phase II trial of homoharringtonine with imatinib in chronic, accelerated, and blast phase chronic myeloid leukemia.
|
Academic Article
|
Long-term follow-up of patients receiving allogeneic stem cell transplant for chronic lymphocytic leukaemia: mixed T-cell chimerism is associated with high relapse risk and inferior survival.
|
Academic Article
|
Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents.
|
Academic Article
|
Characteristics, outcomes, prognostic factors and treatment of patients with T-cell prolymphocytic leukemia (T-PLL).
|
Academic Article
|
Factors associated with risk of central nervous system relapse in patients with non-core binding factor acute myeloid leukemia.
|
Academic Article
|
TP53 mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyper-CVAD-based regimens.
|
Academic Article
|
Morphologic and Molecular Characteristics of De Novo AML With JAK2 V617F Mutation.
|
Academic Article
|
A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia.
|
Academic Article
|
Activation of the B-cell receptor successively activates NF-?B and STAT3 in chronic lymphocytic leukemia cells.
|
Academic Article
|
Clinical characteristics and outcomes of previously untreated patients with adult onset T-acute lymphoblastic leukemia and T-lymphoblastic lymphoma with hyper-CVAD based regimens.
|
Academic Article
|
Long-term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib.
|
Academic Article
|
Outcomes of adults with relapsed or refractory Burkitt and high-grade B-cell leukemia/lymphoma.
|
Academic Article
|
Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients.
|
Academic Article
|
Consolidation treatment with lenalidomide following front-line or salvage chemoimmunotherapy in chronic lymphocytic leukemia.
|
Academic Article
|
Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini-Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Phase 2 Clinical Trial.
|
Academic Article
|
Phase 1 dose escalation multicenter trial of pracinostat alone and in combination with azacitidine in patients with advanced hematologic malignancies.
|
Academic Article
|
Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B-cell function and inhibition of the PD-1/PD-L1 pathway.
|
Academic Article
|
A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia.
|
Academic Article
|
Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN.
|
Academic Article
|
The absolute percent deviation of IGHV mutation rather than a 98% cut-off predicts survival of chronic lymphocytic leukaemia patients treated with fludarabine, cyclophosphamide and rituximab.
|
Academic Article
|
Calreticulin as a novel B-cell receptor antigen in chronic lymphocytic leukemia.
|
Academic Article
|
Ibrutinib inhibits free fatty acid metabolism in chronic lymphocytic leukemia.
|
Academic Article
|
Sustained long-lasting responses after lenalidomide discontinuation in patients with chronic lymphocytic leukemia.
|
Academic Article
|
Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis.
|
Academic Article
|
The CXCR4-STAT3-IL-10 Pathway Controls the Immunoregulatory Function of Chronic Lymphocytic Leukemia and Is Modulated by Lenalidomide.
|
Academic Article
|
MYC protein expression is an important prognostic factor in acute myeloid leukemia.
|
Academic Article
|
Clinical implications of cancer gene mutations in patients with chronic lymphocytic leukemia treated with lenalidomide.
|
Academic Article
|
Final results of a phase 2, open-label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome.
|
Academic Article
|
Early results of lower dose dasatinib (50?mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia.
|
Academic Article
|
Association of bone marrow fibrosis with inferior survival outcomes in chronic myelomonocytic leukemia.
|
Academic Article
|
A Pilot Phase II Study of Erlotinib for the Treatment of Patients with Relapsed/Refractory Acute Myeloid Leukemia.
|
Academic Article
|
STAT3 is constitutively acetylated on lysine 685 residues in chronic lymphocytic leukemia cells.
|
Academic Article
|
A phase II study of omacetaxine mepesuccinate for patients with higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia after failure of hypomethylating agents.
|
Academic Article
|
Why Is the Immunoglobulin Heavy Chain Gene Mutation Status a Prognostic Indicator in Chronic Lymphocytic Leukemia?
|
Academic Article
|
Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial.
|
Academic Article
|
Phase I study of ruxolitinib in previously treated patients with low or intermediate-1 risk myelodysplastic syndrome with evidence of NF-kB activation.
|
Academic Article
|
A prospective analysis of symptom burden for patients with chronic myeloid leukemia in chronic phase treated with frontline second- and third-generation tyrosine kinase inhibitors.
|
Academic Article
|
Initial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia.
|
Academic Article
|
STAT3-activated CD36 facilitates fatty acid uptake in chronic lymphocytic leukemia cells.
|
Academic Article
|
Serial minimal residual disease (MRD) monitoring during first-line FCR treatment for CLL may direct individualized therapeutic strategies.
|
Academic Article
|
Sorafenib Combined with 5-azacytidine in Older Patients with Untreated FLT3-ITD Mutated Acute Myeloid Leukemia.
|
Academic Article
|
Biclonal IGHV-4-34 hairy cell leukemia variant and CLL - successful treatment with ibrutinib and venetoclax.
|
Academic Article
|
Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation.
|
Academic Article
|
Late relapse in acute myeloid leukemia (AML): clonal evolution or therapy-related leukemia?
|
Academic Article
|
Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia.
|
Academic Article
|
Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial.
|
Academic Article
|
Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs.
|
Academic Article
|
Routine sequencing in CLL has prognostic implications and provides new insight into pathogenesis and targeted treatments.
|
Academic Article
|
Efficacy and predictors of response of lenalidomide and rituximab in patients with treatment-naive and relapsed CLL.
|
Concept
|
Myeloid Cell Leukemia Sequence 1 Protein
|
Academic Article
|
Ibrutinib and Venetoclax for First-Line Treatment of CLL.
|
Academic Article
|
Association of gene mutations with time-to-first treatment in 384 treatment-naive chronic lymphocytic leukaemia patients.
|
Academic Article
|
The landscape of genetic mutations in patients with chronic lymphocytic leukaemia and complex karyotype.
|
Academic Article
|
Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study.
|
Academic Article
|
Efficacy and safety of generic imatinib after switching from original imatinib in patients treated for chronic myeloid leukemia in the United States.
|
Academic Article
|
Minimal residual disease undetectable by next-generation sequencing predicts improved outcome in CLL after chemoimmunotherapy.
|
Academic Article
|
Long-term follow-up of lower dose dasatinib (50?mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia.
|
Academic Article
|
STAT3-Induced Wnt5a Provides Chronic Lymphocytic Leukemia Cells with Survival Advantage.
|
Academic Article
|
The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphia-negative B-cell acute lymphoblastic leukemia is a strong predictor for survival.
|
Academic Article
|
The BET inhibitor GS-5829 targets chronic lymphocytic leukemia cells and their supportive microenvironment.
|
Academic Article
|
Achieving complete remission in CLL patients treated with ibrutinib: clinical significance and predictive factors.
|
Academic Article
|
Long-term results of frontline dasatinib in chronic myeloid leukemia.
|
Academic Article
|
Long-term results of a phase 2 trial of nilotinib 400?mg twice daily in newly diagnosed patients with chronic-phase chronic myeloid leukemia.
|
Academic Article
|
A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia.
|
Academic Article
|
Isavuconazole as Primary Antifungal Prophylaxis in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-label, Prospective, Phase 2 Study.
|
Academic Article
|
Targeted next-generation sequencing of circulating cell-free DNA vs bone marrow in patients with acute myeloid leukemia.
|
Academic Article
|
Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortality.
|
Academic Article
|
Phase I/II study of dasatinib in combination with decitabine in patients with accelerated or blast phase chronic myeloid leukemia.
|
Academic Article
|
10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.
|
Academic Article
|
Translocation t(1;19)(q23;p13) in adult acute lymphoblastic leukemia - a distinct subtype with favorable prognosis.
|
Academic Article
|
CXCL13 plasma levels function as a biomarker for disease activity in patients with chronic lymphocytic leukemia.
|
Academic Article
|
Clinical outcomes and influence of mutation clonal dominance in oligomonocytic and classical chronic myelomonocytic leukemia.
|
Academic Article
|
Phase 2 study of lenalidomide maintenance for patients with high-risk acute myeloid leukemia in remission.
|
Academic Article
|
STAT3 induces the expression of GLI1 in chronic lymphocytic leukemia cells.
|
Academic Article
|
Activity of venetoclax-based therapy in chronic myelomonocytic leukemia.
|
Academic Article
|
A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome.
|
Academic Article
|
Single-center experience with venetoclax combinations in patients with newly diagnosed and relapsed AML evolving from MPNs.
|
Academic Article
|
Long-term results of low-intensity chemotherapy with clofarabine or cladribine combined with low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia.
|
Academic Article
|
Clinicopathologic correlates and natural history of atypical chronic myeloid leukemia.
|
Academic Article
|
Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations.
|
Academic Article
|
Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 Trial.
|
Academic Article
|
Activation and expansion of T-follicular helper cells in chronic lymphocytic leukemia nurselike cell co-cultures.
|
Academic Article
|
A multi-arm phase Ib/II study designed for rapid, parallel evaluation of novel immunotherapy combinations in relapsed/refractory acute myeloid leukemia.
|
Academic Article
|
STAT3 Activates the Pentraxin 3 Gene in Chronic Lymphocytic Leukemia Cells.
|
Academic Article
|
TP53-altered chronic lymphocytic leukemia treated with firstline Bruton's tyrosine kinase inhibitor-based therapy: A retrospective analysis.
|